RxDoctor Payments Data

Anthony Sims, MD

Family Medicine · Henagar, ALNPI 1992786636

Payments from drug & device makers

$6,731in general payments, 2019–2025

Across 445 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$752
  • Lilly USA, LLC$523
  • Pfizer$419
  • GSK$387
  • Amgen$303
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,726100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,731 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$176,702
Medicare patients
426
Services billed
4,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin346$282,305
MounjaroTirzepatide205$239,384
EliquisApixaban316$213,710
OzempicSemaglutide155$170,023
FarxigaDapagliflozin Propanediol178$130,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter112$84,063
JanuviaSitagliptin Phosphate101$64,931
XareltoRivaroxaban85$64,225
MyrbetriqMirabegron49$30,626
EntrestoSacubitril/Valsartan57$29,653
VraylarCariprazine Hcl17$29,331
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl145$26,361
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen993$24,930
Synjardy XrEmpagliflozin/Metformin Hcl25$23,382
RybelsusSemaglutide13$21,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$108$305,687371 claims
Lilly USA, LLCMounjaro, Trulicity$523$257,445224 claims
PfizerEliquis, Abrysvo$419$222,304344 claims
Novo NordiskOzempic, Rybelsus$1,076$191,486168 claims
AstraZenecaFarxiga$250$130,083178 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta$387$117,486208 claims
MerckJanuvia, Janumet$243$83,296118 claims
Johnson & JohnsonXarelto$178$64,22585 claims
AbbVieVraylar, Linzess, Ubrelvy$752$58,42756 claims
Astellas Pharma US IncMyrbetriq$46$30,62649 claims
NovartisEntresto$285$29,65357 claims
AmgenProlia$303$20,40112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Henagar

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →